So-Young(US:SY) Xin Lang Cai Jing·2026-01-29 05:56Core Viewpoint - The CEO of New Oxygen Group, Jin Xing, stated that the friction with upstream suppliers has not significantly impacted the company's business, despite some suppliers expressing concerns about the company's pricing strategy and product sourcing [1][2][6]. Group 1: Pricing Strategy and Market Impact - In September 2025, New Oxygen launched the "Youth Needle" product priced at 2999 yuan, which is significantly lower than the market price of over 10,000 yuan, disrupting the existing pricing structure of upstream manufacturers [1][6]. - Despite backlash from several upstream manufacturers, including claims of unauthorized product sourcing and training issues, sales of the "Youth Needle" reportedly surged in October, November, and December 2025, indicating strong consumer acceptance [2][6][7]. Group 2: Business Expansion and Partnerships - As of January 8, 2026, New Oxygen has established 50 clinics across 16 cities and achieved a cumulative treatment volume of 1 million [3][6]. - New Oxygen announced the formation of the "Youth Premium Alliance" with 14 upstream manufacturers, aiming to enhance collaboration through price-volume linkage, tiered supply, training, and product traceability [3][6]. Group 3: Industry Dynamics and Future Outlook - The medical beauty industry is experiencing a shift towards a buyer's market, with an increasing number of suppliers providing more options for medical institutions, which can now select long-term partners and customize products based on their needs [4][7]. - The industry has seen a significant increase in the issuance of medical device certifications, with 52 Class III medical device certificates issued in 2025, suggesting a growing supply landscape [4][7].